respiratori
tract
infect
signific
contributor
global
burden
respiratori
tract
ill
million
death
worldwid
sever
pathogen
includ
virus
bacteria
caus
respiratori
tract
infect
clinic
present
often
overlap
identif
underli
pathogen
base
sole
clinic
criteria
challeng
even
though
respiratori
tract
infect
selflimit
immunocompet
host
mani
treat
shown
recent
studi
highlight
increas
unnecessari
antibiot
use
group
patient
group
includ
immunocompromis
patient
elderli
patient
critic
ill
patient
complic
respiratori
tract
infect
often
occur
poor
outcom
includ
increas
morbid
mortal
thu
abil
rapidli
accur
diagnos
respiratori
tract
infect
critic
optim
patient
care
addit
rapid
accur
diagnosi
essenti
time
administr
antivir
therapi
avail
institut
contact
droplet
precaut
prevent
health
careassoci
transmiss
sever
instrument
multiplex
molecular
panel
current
approv
us
food
drug
administr
fda
rapid
sensit
detect
viral
bacteri
respiratori
pathogen
nasopharyng
swab
np
specimen
method
differ
base
sever
criteria
includ
degre
multiplex
target
complex
method
moder
high
throughput
low
high
turnaround
time
tat
h
h
gener
perform
characterist
multiplex
panel
significantli
better
convent
method
includ
viral
cultur
antigen
test
replac
method
mani
laboratori
hand
increas
cost
multiplex
molecular
panel
compar
cost
convent
method
rais
question
costbenefit
ratio
particularli
mani
viral
target
panel
specif
treatment
howev
given
util
rapid
diagnosi
infect
especi
immunocompromis
patient
infect
control
prevent
practic
antibiot
stewardship
interest
multiplex
pcr
remain
high
genmark
respiratori
pathogen
rp
panel
qualit
nucleic
acid
multiplex
test
recent
receiv
us
fda
clearanc
use
genmark
new
eplex
instrument
eplex
rp
panel
detect
common
respiratori
pathogen
np
specimen
viral
target
identifi
adenoviru
coronaviru
human
metapneumoviru
hmpv
human
rhinovirusenteroviru
hrvev
influenza
viru
influenza
viru
influenza
viru
influenza
viru
influenza
b
viru
parainfluenza
viru
respiratori
syncyti
viru
subtyp
rsva
rsvb
bacteri
target
identifi
chlamydia
pneumonia
mycoplasma
pneumonia
eplex
rp
panel
sampletoansw
multiplex
assay
run
singleus
cartridg
autom
aspect
nucleic
acid
test
includ
extract
amplif
detect
combin
electrowet
microfluid
genmark
esensor
technolog
base
principl
competit
dna
hybrid
electrochem
detect
previous
describ
genmark
respiratori
viral
panel
multicent
clinic
trial
studi
perform
characterist
investigationaluseonli
iuo
eplex
rp
panel
evalu
use
np
specimen
collect
site
across
unit
state
canada
reproduc
evalu
site
addit
assay
perform
characterist
includ
assay
workflow
turnaround
time
evalu
studi
popul
includ
patient
age
gender
present
sign
andor
symptom
upper
respiratori
tract
infect
clinic
site
locat
unit
state
canada
residu
np
specimen
prospect
collect
march
august
site
frozen
futur
test
prospect
collect
septemb
octob
site
test
fresh
supplement
result
prospect
collect
np
sampl
posit
lowpreval
pathogen
retrospect
collect
frozen
frozen
sampl
thaw
pipet
separ
aliquot
frozen
test
eplex
rp
biofir
rp
andor
targetspecif
pcrbidirect
sequenc
need
also
lowpreval
pathogen
addit
contriv
sampl
use
evalu
assay
perform
np
specimen
prospect
retrospect
collect
viral
transport
medium
handl
process
accord
np
kit
manufactur
instruct
either
sampl
collect
specif
studi
separ
standardofcar
soc
purpos
residu
sampl
deidentifi
provid
soc
complet
studi
approv
central
quorum
review
institut
review
board
andor
individu
clinic
test
site
institut
review
board
sampl
test
eplex
rp
panel
site
compar
result
test
biofir
filmarray
respiratori
panel
version
durham
nc
analyt
valid
pcr
amplif
assay
follow
bidirect
sequenc
necessari
eg
resolut
discord
result
viru
subtyp
laboratori
corpor
america
morrisvil
nc
test
eplex
rp
panel
perform
accord
manufactur
instruct
use
materi
kit
briefli
vortex
primari
np
sampl
aspir
sampl
deliveri
devic
sdd
provid
eplex
rp
panel
kit
vortex
entir
volum
sdd
dispens
sampl
load
port
eplex
rp
panel
cartridg
cap
depress
close
port
cartridg
barcod
scan
eplex
instrument
insert
avail
bay
fig
upon
complet
assay
run
eplex
instrument
eject
cartridg
dispos
eplex
rp
panel
report
gener
compar
method
biofir
filmarray
respiratori
panel
version
collect
sampl
test
biofir
rp
detect
respiratori
viral
bacteri
target
includ
eplex
rp
panel
differenti
rsv
subtyp
b
sampl
rsv
detect
biofir
rp
addit
test
analyt
valid
pcr
amplif
assay
follow
confirm
bidirect
sequenc
determin
subtyp
laboratori
corpor
america
morrisvil
nc
result
collect
sampl
discord
eplex
rp
panel
compar
method
ie
fals
neg
fn
fals
posit
fp
test
analyt
valid
pcr
amplif
assay
follow
bidirect
sequenc
describ
coronavirus
addit
repeat
test
biofir
rp
eplex
rp
panel
also
conduct
part
discordantresult
resolut
three
reproduc
panel
pathogen
influenza
viru
rsva
hmpv
coronaviru
adenoviru
speci
b
differ
concentr
moder
limit
detect
lod
low
lod
neg
np
specimen
test
site
lod
studi
perform
manufactur
data
shown
reproduc
test
perform
oper
site
oper
test
reproduc
panel
triplic
day
includ
nonconsecut
day
use
differ
cartridg
lot
result
day
test
lot
posit
percent
agreement
ppa
neg
percent
agreement
npa
overal
percent
agreement
opa
compar
method
result
expect
result
determin
target
detect
eplex
rp
panel
ppa
calcul
tp
tp
fn
npa
calcul
tn
tn
fp
opa
calcul
tp
tn
tp
tn
fp
fn
tp
trueposit
result
fn
falseneg
result
tn
trueneg
result
fp
falseposit
result
twosid
score
confid
interv
ci
calcul
ppa
npa
opa
statist
analysi
perform
use
sa
version
time
studi
perform
determin
time
need
perform
eplex
rp
panel
test
data
averag
sampl
test
oper
step
process
sampl
prepar
unload
instrument
record
time
averag
tat
determin
total
prospect
collect
retrospect
collect
contriv
sampl
elig
test
eplex
rp
panel
approxim
sampl
collect
copanmanufactur
utm
univers
transport
medium
collect
remel
medium
demograph
inform
evalu
prospect
retrospect
collect
subject
sampl
provid
tabl
approxim
subject
male
median
age
year
subject
prospect
collect
sampl
year
subject
retrospect
collect
sampl
preval
eplex
rp
panel
target
age
group
two
phase
prospect
collect
provid
tabl
supplement
materi
sampl
elig
test
eplex
rp
panel
invalid
result
repeat
test
sampl
evalu
due
final
invalid
result
prospect
sampl
contriv
sampl
final
valid
rate
ci
eplex
rp
panel
detect
potenti
respiratori
pathogen
prospect
collect
np
specimen
test
posit
rate
ppa
npa
ci
eplex
rp
panel
target
compar
method
provid
tabl
separ
retrospect
collect
sampl
prospect
collect
sampl
sampl
combin
addit
data
fresh
frozen
prospect
collect
sampl
present
tabl
supplement
materi
overal
percent
agreement
eplex
rp
biofir
rp
result
target
test
ppa
rang
ci
coronavirus
ci
influenza
viru
npa
ci
ci
respect
tabl
sampl
eplex
rp
neg
influenza
viru
target
posit
either
n
n
subtyp
sampl
posit
influenza
viru
target
without
subtyp
identifi
note
influenza
viru
detect
chlamydia
pneumonia
n
isol
detect
studi
period
target
least
specimen
pathogen
spike
neg
np
specimen
contriv
detect
eplex
rp
data
shown
discord
resolut
result
tabl
demonstr
eplex
rp
high
level
agreement
biofir
rp
detect
target
nearli
sampl
assay
detect
target
tabl
sampl
target
detect
eplex
rp
detect
biofir
rp
fp
count
trueposit
sampl
target
detect
discord
test
tpd
sampl
target
detect
eplex
rp
detect
biofir
rp
fn
count
trueneg
sampl
target
detect
discord
test
tnd
given
number
discord
sampl
two
panel
coronaviru
detect
addit
repeat
test
biofir
rp
eplex
rp
perform
part
discord
analysi
addit
test
demonstr
evid
decreas
sampl
stabil
time
variabl
aliquot
test
thu
coronavirus
fn
sampl
count
trueposit
sampl
target
detect
repeat
test
eplex
rp
tpd
total
sampl
test
pcr
assay
varieti
reason
includ
insuffici
volum
repeat
test
includ
sampl
fn
result
coronaviru
hmpv
hrvev
influenza
viru
sampl
fp
hrvev
result
prospect
collect
sampl
codetect
least
one
assay
data
shown
eplex
rp
panel
identifi
total
prospect
sampl
multipl
pathogen
detect
prospect
collect
sampl
biofir
rp
detect
total
sampl
multipl
pathogen
prospect
collect
sampl
sampl
multipl
pathogen
detect
eplex
rp
two
pathogen
three
pathogen
four
pathogen
detect
sampl
codetect
sampl
includ
one
pathogen
detect
biofir
rp
method
compar
method
identifi
total
codetect
one
pathogen
identifi
eplex
rp
panel
discord
resolut
result
includ
analysi
present
tabl
site
perform
reproduc
studi
collect
result
target
concentr
total
sampl
per
site
moder
posit
neg
panel
percent
agreement
ci
panel
target
lowposit
panel
percent
agreement
ci
panel
target
remain
adenoviru
panel
target
percent
agreement
lowposit
panel
ci
agreement
result
shown
tabl
total
sampl
yield
valid
result
upon
initi
test
upon
repeat
test
one
specimen
yield
valid
result
final
valid
rate
ci
signific
sourc
variabl
found
target
panel
across
cartridg
lot
oper
day
technologistsoper
site
data
shown
time
identif
receipt
result
determin
h
min
handson
time
hot
per
sampl
min
multicent
clinic
studi
perform
characterist
new
eplex
respiratori
pathogen
panel
genmark
eplex
instrument
estim
measur
agreement
result
biofir
rp
commerci
avail
multiplex
respiratori
panel
eplex
rp
panel
recent
fda
clear
expand
avail
option
laboratori
interest
rapid
diagnosi
respiratori
tract
infect
use
broadli
multiplex
molecular
assay
np
specimen
similar
biofir
rp
eplex
rp
offer
larg
panel
viral
bacteri
respiratori
pathogen
simpl
sampletoansw
format
minim
handson
time
rapid
turnaround
time
result
molecular
diagnost
test
method
biofir
rp
eplex
rp
potenti
gener
falseposit
falseneg
result
confirm
studi
addit
test
targetspecif
pcr
bidirect
sequenc
unavail
establish
gold
standard
prevent
true
measur
correct
requir
use
agreement
measur
nonrefer
standard
instead
establish
perform
characterist
new
test
thu
data
present
studi
reflect
agreement
result
two
platform
spite
limit
overal
perform
eplex
rp
compar
biofir
rp
overal
percent
agreement
trueposit
trueneg
result
avail
target
test
line
result
recent
studi
nijhui
colleagu
evalu
perform
eplex
researchuseonli
ruo
rp
panel
compar
laboratorydevelop
assay
found
overal
agreement
discord
result
occur
primarili
sampl
low
pathogen
load
estim
use
cycl
threshold
ct
valu
ie
high
ct
valu
highest
number
discord
result
observ
adenoviru
coronaviru
rhinovirusenteroviru
target
find
may
explain
larg
divers
genotyp
present
within
group
pathogen
preval
pathogen
popul
test
adenoviru
perform
diagnost
test
particularli
import
young
children
immunocompromis
host
howev
detect
adenoviru
challeng
studi
eplex
rp
detect
adenovirus
biofir
rp
recent
report
perform
biofir
rp
detect
adenoviru
highlight
decreas
sensit
assay
sampl
low
viral
load
posit
speci
f
although
eplex
rp
panel
detect
genotyp
coronavirus
result
report
without
genotyp
inform
current
treatment
coronavirus
util
genotyp
inform
may
lie
valu
epidemiolog
studi
report
sever
coronaviru
infect
report
immunocompromis
host
indic
sever
associ
particular
genotyp
similar
biofir
rp
eplex
rp
detect
wide
rang
rhinoviru
enterovirus
genotyp
given
high
degre
genet
similar
reliabl
differenti
two
speci
base
discord
analysi
perform
pcr
bidirect
sequenc
sampl
posit
rhinoviru
trend
expect
given
rhinovirus
common
caus
common
cold
overal
agreement
influenza
virus
high
prospect
collect
period
clinic
studi
occur
respiratori
season
expect
lack
clinic
specimen
posit
influenza
viru
influenza
viru
infect
time
period
due
virus
henc
evalu
influenza
viru
target
perform
entir
use
contriv
np
sampl
similar
biofir
rp
result
instanc
sampl
posit
influenza
viru
without
subtyp
posit
influenza
viru
subtyp
identifi
result
may
caus
low
viru
titer
novel
influenza
viru
subtyp
thu
requir
addit
test
limit
number
sampl
posit
chlamydia
pneumonia
evalu
conduct
primarili
contriv
sampl
perform
c
pneumonia
similar
report
biofir
rp
clinic
studi
also
conduct
use
primarili
contriv
sampl
chlamydia
pneumonia
mycoplasma
pneumonia
associ
atyp
communityacquir
pneumonia
cap
season
nonspecif
symptom
therefor
inclus
bacteria
larg
multiplex
panel
potenti
significantli
improv
diagnosi
cap
notabl
differ
eplex
rp
panel
biofir
rp
absenc
bordetella
pertussisbordetella
parapertussi
target
among
bacteri
target
noteworthi
unlik
bacteri
target
panel
infect
bordetella
pertussisb
parapertussi
rel
specif
epidemiolog
higher
incid
typic
report
children
less
month
old
recent
unvaccin
popul
vaccin
patient
wane
immun
thu
exclus
highli
multiplex
respiratori
panel
may
warrant
addit
util
singlecopi
pertussi
toxin
promot
target
ptxp
multiplex
panel
shown
less
sensit
detect
b
pertussi
pcr
test
target
multicopi
insert
sequenc
result
b
pertussi
infect
suspect
fdaclear
b
pertussi
molecular
test
may
appropri
similar
broadli
multiplex
respiratori
panel
eplex
rp
panel
allow
detect
coinfect
studi
coinfect
identifi
sampl
human
rhinovirusenteroviru
common
viru
detect
coinfect
specimen
import
detect
coinfect
highlight
recent
studi
show
viralbacteri
coinfect
sever
cap
adult
result
complic
diseas
cours
associ
complic
studi
human
rhinovirus
frequent
detect
associ
bacteri
pathogen
hematopoiet
stem
cell
transplant
popul
suggest
commonli
detect
viru
may
signific
caus
sever
pneumonia
immunocompromis
patient
initi
rate
invalid
result
eplex
rp
repeat
test
result
final
rate
invalid
result
valu
fall
rang
rate
invalid
result
report
multiplex
respiratori
panel
includ
nanospher
verigen
rv
xtag
rvp
biofir
rp
eplex
instrument
consist
standalon
system
addit
accessori
eg
comput
touch
screen
make
great
option
spaceconstrain
laboratori
eplex
instrument
avail
configur
rang
one
four
tower
tower
contain
six
randomaccess
test
bay
support
singleshift
h
test
volum
rang
sampl
sampl
tat
less
h
hot
less
min
provid
flexibl
capac
laboratori
size
addit
featur
avail
system
includ
abil
gener
custom
report
eg
statist
trend
report
potenti
bidirect
interfac
laboratori
inform
system
conclus
eplex
rp
panel
provid
rapid
sensit
broadli
multiplex
sampletoresult
option
minim
handson
time
assay
perform
equival
biofir
filmarray
rp
target
new
fulli
integr
instrument
easili
expand
offer
great
option
implement
multiplex
assay
largervolum
laboratori
